Wegovy heart benefits: what the clinical evidence actually shows

Where the heart evidence comes from: SELECT and the MHRA's decision

The cardiovascular case for semaglutide rests primarily on the SELECT trial — a phase 3, placebo-controlled study that enrolled 17,604 adults aged 45 and over with overweight or obesity (BMI 27 or above) and pre-existing cardiovascular disease, but without type 2 diabetes. Over a median of around five years, participants receiving weekly semaglutide 2.4mg experienced a 20% lower risk of a three-point MACE outcome: non-fatal heart attack, non-fatal stroke, or death from cardiovascular causes. You can read the full trial data via the New England Journal of Medicine's SELECT publication.

What made SELECT noteworthy beyond the headline figure was the consistency of the finding. Risk reduction appeared across subgroups defined by baseline BMI, age, and geographic region. Crucially, when researchers looked at participants who lost relatively little weight, the cardiovascular benefit was still present, suggesting that GLP-1 receptor agonism may act on the heart through pathways that go beyond body-weight reduction. Researchers have proposed several mechanisms: reduced systemic inflammation, improvements in blood pressure and lipid profiles, and direct effects on cardiac and vascular tissue.

Following SELECT, the MHRA approved an additional UK indication for Wegovy specifically for reducing cardiovascular risk. The NHS England overview of weight management injections discusses both the weight-management and cardiovascular contexts for semaglutide. This is distinct from the weight-management licence, the two are separate authorisations, and prescribers consider them separately.

How the heart benefits of Wegovy sit alongside its weight-loss effects

It is tempting to treat the heart health story as a downstream consequence of losing weight. Weight loss does improve many cardiovascular risk factors (blood pressure, cholesterol, blood glucose, sleep apnoea) and Wegovy produces clinically meaningful weight reduction. The STEP 1 trial reported around 15% average body-weight reduction over 68 weeks at the 2.4mg maintenance dose, as published in the New England Journal of Medicine.

But the SELECT findings add a layer to that picture. Because cardiovascular risk reduction was seen in participants with varying degrees of weight loss, the evidence points toward at least a partial independent mechanism. GLP-1 receptors are expressed in cardiac tissue; preclinical and early clinical studies suggest semaglutide may reduce inflammatory markers such as C-reactive protein and interleukin-6. Blood pressure improvements observed in SELECT participants were modest in absolute terms but consistent.

None of this replaces the lifestyle and medical management that people with established cardiovascular disease already receive. Semaglutide in the SELECT population was prescribed on top of standard-of-care background therapy (statins, antihypertensives, antiplatelet agents) not instead of it. For anyone considering Wegovy, the conversation about its effects on the heart is one for their prescriber, who can weigh individual history against the evidence.

Who the cardiovascular indication actually applies to

The UK cardiovascular licence for Wegovy applies to adults with a BMI of 27 or above who have established cardiovascular disease, defined in SELECT as prior heart attack, prior stroke, or symptomatic peripheral arterial disease. This is not the same population as the weight-management indication, and BMI thresholds for cardiovascular eligibility are separate from those NICE sets for weight management under TA875.

Lower BMI thresholds may apply for people from South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean backgrounds, in line with UK clinical guidance on ethnicity-adjusted criteria. The overlap between the two indications is considerable in practice (many adults who would qualify on cardiovascular grounds also qualify for weight management) but a prescriber assesses the full clinical picture before issuing any prescription.

It is worth noting that the cardiovascular indication is for secondary prevention, meaning people who have already had a cardiovascular event or have significant cardiovascular disease. It does not currently extend to primary prevention (reducing risk in people with no established disease). Questions about how Wegovy interacts with the heart more broadly (including its effects on heart rate) are worth raising directly with a clinician, since individual histories vary considerably. Our clinical team reviews every consultation personally before any prescription is issued.

Practical considerations if you are thinking about Wegovy for heart health

Wegovy is a prescription-only medicine in both its weight-management and cardiovascular indications. The path to a legitimate prescription begins with a thorough clinical assessment, medical history, current medications, and weight profile all feed into whether it is appropriate. People already taking medicines for heart disease need their prescriber to check for any relevant interactions before starting.

A small practical point worth mentioning: once prescribed, each pen is stored in the fridge at 2–8°C, some people keep them in the fridge door alongside everyday items, which works well as a reminder for the weekly injection. Storage specifics are covered in the Patient Information Leaflet supplied with each pen.

Side effects are mostly gastrointestinal, nausea, loose stools, and reflux are most common when first starting or after a dose increase, and they tend to settle within a couple of weeks for most people. Anyone experiencing severe or persistent abdominal pain that radiates to the back should seek urgent medical attention, in line with MHRA guidance on pancreatitis as a known but infrequent risk with GLP-1 medicines. Some patients also ask whether GLP-1 medicines affect their relationship with alcohol, and our page on whether Wegovy helps you stop drinking explores what the current evidence suggests. You can explore our full Wegovy overview for a broader picture of how the medicine works.

If you have established heart disease and are wondering whether you might be a candidate for Wegovy, a free consultation with a GPhC-registered Independent Prescriber is the right starting point. You can also review Wegovy pricing information before you start. Check your eligibility and speak to our prescribers today.